DDInter1115 DDInter1658
Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Magnesium citrate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Magnesium citrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Arsenic trioxide
Magnesium citrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Magnesium citrate {u} may lead to a major life threatening interaction when taken with {v} Dolutegravir
Magnesium citrate {u} may lead to a major life threatening interaction when taken with {v} Bictegravir
Magnesium citrate may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Magnesium citrate may lead to a major life threatening interaction when taken with Dolutegravir
Magnesium citrate may lead to a major life threatening interaction when taken with Bictegravir